About
NRx Pharmaceuticals is a clinical biopharmaceutical company developing treatments for severe bipolar depression, suicidality, and PTSD. Its lead programs include NRX-100 (ketamine) and NRX-101, an oral investigational therapy for suicidal bipolar depression currently in FDA trials.
Explore NRx Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.